BIOA
BioAge Labs, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
7,861 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
4,000 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. |
Common Stock
|
20,216 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
4,000 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
4,065 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
4,290 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
4,065 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
7,861 |
| 2026-06-30 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
4,290 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
7,261 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
14,198 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
7,261 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
14,198 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
8,958 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Common Stock
|
9,301 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
8,958 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
9,301 |
| 2026-06-29 | Barton Shane |
Principal Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
42,350 |
| 2026-06-10 | Davidson Michael H. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-06-10 | Pande Vijay Satyanand |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-06-10 | ENRIGHT PATRICK G |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-06-10 | GARNIER JEAN PIERRE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-06-10 | HEALY JAMES |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-06-10 | Hemrajani Rekha |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Stock Option (Right to Buy)
|
22,000 |
| 2026-04-23 | GOLDSTEIN DOV A MD |
Director |
Convert↑
|
Common Stock
|
3,542 |
| 2026-04-23 | GOLDSTEIN DOV A MD |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
3,542 |
| 2026-04-01 | RUBIN PAUL D |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
8,820 |
| 2026-04-01 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
3,383 |
| 2026-04-01 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |
Stock Option (Right to Buy)
|
5,437 |
| 2026-04-01 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
3,383 |
| 2026-04-01 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
5,437 |
| 2026-03-02 | RUBIN PAUL D |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
7,433 |
| 2026-03-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
2,000 |
| 2026-03-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |
Stock Option (Right to Buy)
|
5,433 |
| 2026-03-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
5,433 |
| 2026-03-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
2,000 |
| 2026-03-01 | GOLDSTEIN DOV A MD |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
3,542 |
| 2026-03-01 | GOLDSTEIN DOV A MD |
Director |
Convert↑
|
Common Stock
|
3,542 |
| 2026-02-17 | Morgen Eric |
Director, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
110,000 |
| 2026-02-17 | GOLDSTEIN DOV A MD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
110,000 |
| 2026-02-17 | Fortney Kristen |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
330,000 |
| 2026-02-17 | Barton Shane |
Principal Accounting Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
45,000 |
| 2026-02-17 | Morgen Eric |
Director, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date. Represents an employee stock option directly held by the reporting person's spouse. |
Stock Option (Right to Buy)
(I)
|
12,500 |
| 2026-02-17 | RUBIN PAUL D |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
110,000 |
| 2026-02-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
5,433 |
| 2026-02-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
2,000 |
| 2026-02-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
2,000 |
| 2026-02-02 | RUBIN PAUL D |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |
Stock Option (Right to Buy)
|
5,433 |
| 2026-02-02 | RUBIN PAUL D |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
Common Stock
|
7,433 |
| 2026-02-01 | GOLDSTEIN DOV A MD |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
3,541 |